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Abstract: Levo-tetrahydropalmatine (l-THP) is an active constituent of herbal
preparations containing plant species of the genera Stephania and Corydalis
and has been approved and used in China for a number of clinical indications
under the drug name Rotundine. The pharmacological profile of l-THP, which
includes antagonism of dopamine D1 and D2 receptors and actions at
dopamine D3, alpha adrenergic and serotonin receptors, suggests that it may
have utility for treating cocaine addiction. In this review, we provide an
overview of the pharmacological properties of l-THP and the evidence
supporting its development as an anti-addiction medication. The results of
preclinical work demonstrating that l-THP attenuates cocaine’s
reinforcing/rewarding effects and reinstatement in rat models of cocaine
relapse are summarized, and the outcomes of studies demonstrating efficacy
in human addicts are described. Finally, an overview of the safety profile of lTHP is provided and challenges associated with FDA approval of l-THP are
discussed.
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Introduction
Despite intense drug development efforts, the treatment of
cocaine addiction persists as an unmet medical need for which there is
no currently available FDA-approved medication. The impact of cocaine
addiction on society is tremendous, with costs likely in the tens of
billions of dollars [1]. While sizable, the monetary cost of cocaine
addiction is overshadowed by the enormous toll that it takes on the
individual, family, and community. The complexity of cocaine’s
neuropharmacological actions (as a monoamine uptake blocker,
cocaine acutely promotes the actions of dopamine, norepinephrine and
serotonin leading to widespread effects in the brain) and the multifaceted nature of addiction make treatment a significant challenge.
Current treatment strategies consist primarily of cognitive/behavioralbased interventions and have limited efficacy. It is generally
recognized that any significant therapeutic advances will likely stem
from the identification and/or development of medications that target
the neuropathological consequences of long-term cocaine abuse.
Traditionally, drug development approaches aimed at treating
cocaine addiction have been based on the ability of candidate
compounds to attenuate the subjective or positive
reinforcing/rewarding effects of cocaine. However, while mitigating
these effects of cocaine may curb its use, it has become clear that that
a critical attribute of any effective treatment will be its ability to
prevent the sudden onset of drug craving and resultant relapse that
emerges, often unpredictably, even after extended periods of
abstinence from drug use. Since it appears that the neurobiological
processes that underlie craving and relapse are largely distinct from
those that mediate cocaine’s reinforcing/subjective effects, it can be
argued that optimal treatment may require a “cocktail approach”
involving multi-drug therapy or medications with pharmacological
profiles that include actions at multiple receptor targets.
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Pharmacology of L-Tetrahydropalmatine
Drug Properties
Tetrahydropalmatine (THP; C21H25NO4; Chemical name: (13aS)2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1b]isoquinoline; Molecular Weight: 355.43) is a
tetrahydroprotoberberine (THPB) diisoquinoline alkaloid and a primary
active constituent of the herbal plant species Stephania rotunda Lour
(Qianjinteng) and Corydalis ambigua (Yanhusuo). Preparations of
these plants have been used traditionally for their sedative,
neuroleptic and analgesic properties [2]. In particular, the levo isomer
of THP (l-THP; structure shown in Figure 1) appears to contribute to
many of the therapeutic effects of these herbs [3]. Notably, the dextro
isomer of THP has distinct pharmacological actions that include
depletion of monoamines and may contribute to the toxicology profile
of THP-containing preparations or racemic mixtures of the compound
[4, 5]. In addition to serving as an active constituent in traditional
Chinese herbal preparations, purified or synthetic l-THP is approved for
use and available as Rotundine or Rotundin in China [6] where l-THP
has been used as an analgesic and sedative for more than 40 years.

Figure 1 Chemical structure of l-THP
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Metabolism
The metabolism of l-THP involves demethylation at several sites,
with a number of demethylated metabolites identified in urine and
feces [7, 8]. Notably, several of these metabolites can be found in
Corydalis Yanhusuo and may themselves have actions at dopaminergic
receptors and other putative l-THP targets [9], thereby contributing to
the therapeutic effects of l-THP. Further investigation of the
pharmacological profiles of l-THP metabolites will likely be important to
fully understanding the mechanisms that contribute to its apparent
clinical efficacy.

Pharmacological actions at D1, D2, D3 dopamine and
other receptors
Primarily through the efforts of Chinese scientists, most notably led by
Dr. Jin Guozhang, a researcher at the Shanghai Medical Institute,
much has been learned about the pharmacological profile of l-THP. A
large body of evidence suggests that l-THP binds to D1 and D2
dopamine receptors [10-12]. In contrast to other THPB derivatives,
which have partial agonist effects at the D1 dopamine receptor, l-THP
is an antagonist at both of these receptors as defined according to its
minimal stimulation of cAMP production in D1 receptor-expressing HEK
cells relative to dopamine ([13] and Mantsch, unpublished results) and
lack of D2 receptor-mediated mitogenic effects. The Ki values for l-THP
at D1 and D2 dopamine receptors are approximately 124 nM (D1) and
388 nM (D2), while the IC50 values are 166 nM (D1) and 1.4 μM (D2),
respectively (Table 1). The relatively high affinity of l-THP at D1 vs. D2
receptors, distinguishes it from other available dopamine receptor
antagonist drugs (e.g., haloperidol). Although l-THP lacks high affinity
for these receptors, pharmacokinetic data suggest that brain
concentrations of l-THP that are reached following administration of
clinically relevant doses are more than sufficient for occupancy [14]. LTHP also binds to the D3 dopamine receptor ([13] and see Table 1).
Considering that the D3 receptor has been identified as a target of
interest for medications aimed at preventing relapse, blockade of D3
receptors could contribute to the putative utility of l-THP as an antiaddiction agent [15]. However, the affinity of l-THP for the D3 receptor
is considerably lower (1.4 μM) than for D1 and D2 receptors, and the
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IC50 is close to 3.3 μM. Thus, the ability of l-THP to antagonize D3
receptors at clinically relevant doses is unclear. In addition to the
antagonism of post-synaptic dopamine receptors, the blockade of presynaptic autoreceptors by l-THP results in increased dopamine release
[16], and it has been suggested that lower affinity of l-THP for D2
receptors may confer some degree of autoreceptor selectivity [16, 17].
Table 1 l-THP binding profile at monoaminergic receptors*
Receptor

IC50 (nM ±SEM)

Ki (nM ±SEM)

Hill Slope ±
SEM

Dopamine D1

166 ± 8

124 ± 6

−0.84 ± 0.003

Dopamine D2

1470 ± 270

388 ± 78

−1.14 ± 0.13

Dopamine D3

3250 ± 540

1420 ± 220

−1.09 ± 0.14

5-HT1A

374 ± 69

340 ± 63

−0.86 ± 0.12

ND

ND

ND

ND

ND

ND

**

Adrenergic, α 1
Adrenergic, α 2A

***

Data from NIDA sponsored drug screening report (to JBW), except noted.
shows more than 50% inhibition non-selective binding assay at 10μM [7].
***
shows more than 50% inhibition binding assay at 10μM [7].
*

**

ND not determined; SEM standard error of mean

Along with dopamine receptors, l-THP has been reported to
interact with a number of other receptor types, including alpha-1
adrenergic receptors, at which it functions as an antagonist [18], and
gamma-aminobutyric acid (GABA)A receptors, at which it facilitates
GABA binding through positive allosteric effects [19]). Additionally, lTHP displays significant binding to 5-HT1A and alpha-2 adrenergic
receptors (Table 1). In the case of 5-HT1A receptors, l-THP binds with a
Ki of approximately 340 nM and has an IC50 of approximately 370 nM,
concentrations that are likely exceeded in the brain following
administration of l-THP doses that are active in animal models.

Rationale for the Use of l-THP for the Treatment of
Addiction
The contribution of dopamine to cocaine-seeking behavior is
well-characterized [20-22]. As a blocker of dopamine uptake [23],
cocaine increases dopaminergic activity in brain regions critical for
reinforcement, such as the nucleus accumbens, resulting in stimulation
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of post-synaptic dopamine receptors and modulation of behavioral
output from the motive circuit (i.e., drug seeking). Interference with
the activation of dopamine receptors following cocaine administration
has long been thought to represent a promising approach for the
management of cocaine addiction [24]. However, drugs that act as
pure antagonists at D1 and D2 dopamine receptors have proven to be
largely ineffective for treating cocaine addicts, due to the high
incidence of side effects such as sedation and anhedonia and the
ability of drug users to overcome receptor antagonism by selfadministering greater amounts of cocaine [24]. Like other dopamine
receptor antagonists, l-THP attenuates locomotor activity [13, 25],
reduces response rates and breakpoints for sucrose pellet selfadministration [13, 26] and increases thresholds for intracranial selfstimulation [25] – effects that are highly suggestive of sedative and
anhedonic properties. However, it has been suggested that, in contrast
to many other dopamine receptor antagonist drugs, there is separation
between the doses at which l-THP produces these sedative/anhedonic
effects and those that are active in preclinical addiction/abuse models,
suggesting that the pharmacological properties of l-THP may extend
beyond simple D1/D2 receptor antagonism. Validation of this claim will
require additional research directly comparing l-THP with other
dopamine receptor antagonists previously tested for the treatment of
cocaine addiction (e.g., alpha-flupenthixol) and is critical for
demonstration that l-THP does not suffer from the same shortcomings
of these drugs.
Recent investigation of drugs that target dopaminergic
neurotransmission has focused on agents that function as partial
agonists [27, 28], interfere with the activation of D3 dopamine
receptors [29], or have more complex pharmacological profiles with
differential actions at multiple receptor types and locations [30, 31]).
Although other THPB analogs, e.g., levo-stepholidine (l-SPD), have
been shown to be partial agonists at D1 dopamine receptors [32] it
has been demonstrated that l-THP has no intrinsic efficacy at D1
dopamine receptors and therefore likely functions as a D1 receptor
antagonist [13]. Further, despite some indications that D3 receptor
antagonism may contribute to the effects of l-THP in preclinical abuse
models [26] the affinity of l-THP for D3 dopamine receptors is very
low. Thus, it is possible that actions at non-dopaminergic receptors
may account for the effects of l-THP.
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In addition to blocking dopamine clearance through inhibition of
the dopamine transporter, cocaine prevents uptake of both
norepinephrine and serotonin, thereby augmenting noradrenergic and
serotonergic neurotransmission and increasing activation of adrenergic
and serotonergic receptors [33]. Considering the widespread effects of
cocaine on monoaminergic neurotransmission, it should not be
surprising that cocaine addiction is a complex disorder that involves
actions on and dysregulation of multiple receptors, cell types, and
neurobiological systems. Implicit in this understanding is the possibility
that medications that target a single receptor type may not be
adequate for the management of cocaine addiction. Thus, effective
pharmacotherapy may require a “cocktail” approach that involves the
use of more than one medication or drugs such as l-THP with more
complex pharmacological profiles involving action at multiple
receptors. An added benefit of such an approach is that it may permit
additive therapeutic effects while reducing the risk for unwanted side
effects by minimizing occupation of any single receptor.
Although there has been much focus on dopamine receptors as
targets for the development of addiction medications, there is
considerable evidence that serotonin [34] and norepinephrine [35] can
also contribute to cocaine’s effects and influence cocaine-seeking
behavior. For this reason, the ability of l-THP to antagonize cocaineinduced activation of serotonergic (5-HT), adrenergic and
dopaminergic receptors may distinguish it from agents with a more
limited range of action. In particular, secondary effects at alpha-1 and
5-HT1A receptors, or agonist effects at alpha-2 receptors could
contribute to the beneficial effects of l-THP against drug relapse.
Alpha-1 adrenergic {{363 Zhang,X.Y. 2005}} and 5-HT1A [37]
receptor antagonists and alpha-2 agonists [38] have been previously
reported to attenuate cocaine seeking in rats. Secondary actions of lTHP at 5-HT1A and alpha adrenergic receptors could also minimize the
extrapyramidal effects associated with dopamine receptor antagonism
by l-THP [39-41]. The contribution of these mechanisms to the effects
of l-THP will require further investigation. Despite its use as an
analgesic agent, no interaction of l-THP with opioid receptors has been
documented, and its analgesic effects are naloxone-independent [42].
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Preclinical Studies Of L-Thp
The idea that l-THP may represent an effective medication for
treating drug addiction is well-supported by the preclinical animal
literature (see Table 2 for an overview). A variety of experimental
approaches are available for examining different aspects of
abuse/addiction using rodents. Importantly, different assays can be
used to assess the ability of potential treatments to attenuate the
positive reinforcing/rewarding effects of cocaine and cocaine relapse.
One potential issue for interpretation of the actions of l-THP in
behavioral assays, and a concern about its clinical use, is that the drug
has known sedative effects that can interfere with behaviors required
for assessment of drug-seeking behavior. In fact, l-THP has been
widely used in China for its sedative properties. Accordingly, it has
been found that l-THP produces dose-dependent reductions in
locomotor activity and operant responding for non-drug reinforcers in
rats [13, 26, 43]. For this reason, a critical goal of preclinical testing
has been to separate non-specific motor suppressive effects of l-THP
from reductions in drug responsiveness and drug-seeking behavior.
Table 2
Effects of l-THP in preclinical behavioral models of cocaine
abuse/addiction
Preclinical Model

Effects of l-THP

References

FR Cocaine SelfAdministration

Rightward/downward shift in dose-response
curve for self-administration

[14][26]

PR Cocaine SelfAdministration

Decreased breakpoints

[26][27]

Drug Discrimination

Rightward shift in dose-response curve

[27]

Intracranial SelfStimulation

Attenuation of cocaine-induced decreases in
reward threshold

[26]

Cocaine-Induced
Reinstatement

Decreased reinstatement in response to an
intraperitoneal cocaine injection

[14][44]

Cue-Induced
Reinstatement

Decreased reinstatement during response[44]
contingent presentation of cocaine-associated
cues

Stress-Induced
Reinstatement

Decreased reinstatement in response to
footshock stress

[44]
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Actions of l-THP on Cocaine Reward/Reinforcement
The study of the acute positive reinforcing effects of drugs has
relied heavily on preclinical drug self-administration procedures in
which rats are surgically implanted with intravenous catheters and
required to press a lever (or engage in a similar task) in order to
receive drug infusions. The validity of such procedures arises from the
observation that, with few exceptions, drugs that are abused by
humans are also self-administered by rats, while drugs that are not
abused by people (including l-THP) are not. Compounds that alter drug
self-administration by rats often do so by reducing the positive
reinforcing/rewarding effects of drugs and therefore may curb drug
use by human addicts [44][45]. The most basic self-administration
approach involves the use of fixed ratio (FR) schedules under which
drug is delivered every time a rat presses a lever a fixed number of
times. Two studies by different research groups have demonstrated
that, in rats trained to self-administer cocaine under FR schedules, lTHP alters self-administration in a manner that is consistent with a
reduction in the reinforcing effects of cocaine [13, 25]. Mantsch and
colleagues reported that, when the effects of l-THP were tested across
a range of cocaine doses using an approach that involved variation of
cocaine doses during 30-min components within a single selfadministration session, the dose-response curve for self-administration
(0.031 – 1 mg/kg/infusion) was shifted downward and to the right by
l-THP [13]. In the second study by Xi and colleagues [25], it was
found that, when rats were tested for self-administration at a single
higher cocaine dose (0.5 mg/kg/infusion) in the absence of prior
variation in the self-administered cocaine dose, l-THP dosedependently increased responding, a behavioral pattern that is
associated with a reduction in the reinforcing effects of cocaine when
observed under these conditions. Notably, in these studies, l-THP was
effective at doses that failed to alter concurrently-measured [13] or
independently-measured [25]food-reinforced responding under
identical schedules of reinforcement.
A second protocol for examining treatment effects on positive
reinforcement by cocaine involves the use of progressive ratio (PR)
schedules of cocaine self-administration, under which the response
requirement for cocaine delivery progressively increases with each
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successive cocaine infusion. Using this approach, the ability of a
medication to reduce cocaine’s reinforcing efficacy and/or the
motivation to acquire cocaine can be assessed according to changes in
the breakpoint for self-administration, defined as the maximal amount
of work (i.e., lever presses or nose pokes) that the subject will
perform in order to receive the drug [46][47]. Increases and
decreases in breakpoints (i.e., a greater or lesser amount of work
performed to receive the drug) are interpreted as elevations and
reductions in reinforcing efficacy and/or motivation to take the drug,
respectively. It has been suggested that PR schedules offer an
advantage over FR schedules for the determination of changes in
reinforcing efficacy, due to reduced susceptibility to the ratedecreasing (e.g., sedative) effects of drugs and relative ease of
interpretation of findings. L-THP has been reported by two separate
research groups to reduce breakpoints for cocaine self-administration
in rats at doses that fail to alter PR self-administration of a food
reinforcer [25, 26]. When combined with the findings from studies
investigating the effects of l-THP on cocaine self-administration under
FR schedules of reinforcement, these data suggest that l-THP
effectively reduces the reinforcing properties of cocaine, thus
potentially curbing use.
Alterations in the rewarding effects of cocaine can also be
studied using an intracranial self-stimulation (ICSS) approach [48].
With this method, an electrode is implanted into the brain to permit
stimulation of neural pathways subserving reward/reinforcement.
Implanted rats will repeatedly press a lever in order to receive
stimulation. Drugs of abuse such as cocaine will increase sensitivity of
rats to stimulation, as demonstrated by a reduction in the threshold
current for ICSS. L-THP blocks cocaine-induced decreases in ICSS
thresholds at doses that alone fail to increase threshold in a manner
indicative of anhedonic effects [25]. Although these findings suggest
that l-THP does not produce anhedonic effects at doses that can
mitigate cocaine’s effects, it should be noted that effects on ICSS
thresholds in rats with a history of cocaine self-administration have not
been assessed.
Yet another common method for the examining the ability of
treatments to interfere with abuse-related drug effects is the drug
discrimination protocol [49]. Using this approach, rats learn to
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recognize the interoceptive, subjective state (i.e., discriminative
stimulus) produced by cocaine and are trained to emit distinct
response patterns in the presence and absence of cocaine delivery. As
is the case with the reinforcing effects of cocaine, l-THP blocks
cocaine’s discriminative stimulus effects, as observed as a rightward
shift in the dose response curve for cocaine substitution for the
training dose [8]. Also as is observed with the reinforcing effects of
cocaine, l-THP attenuates cocaine discrimination at doses that fail to
produce suppression of response rate [26].

Effects of l-THP in Preclinical Models of Relapse
Although the ability to competitively block cocaine’s acute
subjective and positive reinforcing/rewarding effects may alter use
patterns, it is unlikely that this, by itself, will lead to sustained drug
abstinence. Many addicts enter into treatment during periods of
abstinence in order to prevent drug relapse, which is typically
preceded by craving, or the intense desire to use a drug. A variation of
the self-administration protocol, the reinstatement paradigm, can be
used to study stimuli that induce drug relapse [50]. Using this
approach, relapse can be examined based on the ability of stimuli
reinstate or restore extinguished drug-seeking behavior after it has
been extinguished. Notably, the same stimuli that produce craving and
relapse in humans (drug re-exposure, stress, and exposure to drugassociated cues) also reinstate extinguished cocaine-seeking behavior
in rats [51]. Importantly, the neurobiological substrates that underlie
reinstatement appear to be distinct from those that mediate the
subjective and positive reinforcing/rewarding effects of cocaine. L-THP,
administered ip [13] or orally [43] attenuates reinstatement of
extinguished cocaine seeking in rats in response to a cocaine
challenge, a stressful stimulus (uncontrollable electric footshock), or
response-contingent exposure to a stimulus (tone and light complex)
previously associated with drug delivery in rats. This attenuation was
observed at l-THP doses that failed to alter lever-pressing for a nondrug (i.e., food) reinforcer when tested either concurrently with
reinstatement or in separate groups of rats.
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Clinical Use and Studies Of L-Thp
Pharmacokinetics of l-THP
The pharmacokinetic properties of l-THP are favorable for its
development as an anti-addiction medication. Plasma and tissue levels
of l-THP can be quantified using HPLC. It is well absorbed following
oral administration in both rat and man [14, 52]. In rats, following oral
administration of racemic THP or l-THP, blood levels of l-THP show a
rapid peak within the first hour, followed by a gradual decline,
resulting in a t1/2 of approximately 5 hours [14]. The half-life for l-THP
in man appears to be about 10 hours [53][54], permitting once daily
dosing. L-THP also readily enters the brain [14] with peak levels within
the first hour followed by stable concentrations measured in a number
of brain regions, including the striatum, for the next 4-6 hrs. The
effects of l-THP on cytochrome P450 mediated metabolism of other
drugs appears to be minimal and primarily involve low affinity
inhibition of CYP2D6 [55].

Clinical Uses in China
It has long been recognized that l-THP has therapeutic value for
treating a number of CNS-related conditions. The effectiveness of lTHP as a non-opioid analgesic and sedative/anxiolytic agent resulted in
the approval of purified l-THP for this indication by the Chinese SFDA
(FDA equivalent) and has led to extensive investigation of the
pharmacological properties of l-THP. The suggestion that the
therapeutic effects of l-THP may be partly attributable to dopamine
receptor antagonism [42, 56] has led to the investigation of the
potential utility of l-THP for other disorders known to be associated
with dopaminergic dysfunction, particularly drug addiction. Interest in
l-THP as a medication for treating addiction has peaked with recent
preliminary clinical trials in China that found that l-THP reduces drug
craving and relapse [15] and promotes detoxification [16] in
recovering heroin addicts.
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Clinical Studies in Heroin-Dependent Populations
Although clinical trials examining the potential utility of l-THP for
cocaine addiction have not been conducted, the results of studies
testing for effectiveness in heroin-dependent populations have been
promising. A pilot study testing for the effects of l-THP in heroin users
[57] examined the efficacy of l-THP in reducing craving and relapse
rate in 120 heroin addicts (average of 2-3 heroin uses per day for
about 3 years). In this randomized, double-blind, placebo-controlled
study, patients received 4 weeks of l-THP treatment and three months
follow-up after l-THP treatment during which the severity of the
protracted abstinence (a.k.a., post-acute) withdrawal syndrome
(PAWS), as measured using a Heroin Withdrawal Scale (HWC)
questionnaire, and abstinence rate, determined based on drug-positive
urine tested, were assessed. The HWC questionnaire consisted of selfrating on a 5-point scale of 30 different symptoms in four different
categories: mood, craving, insomnia, and somatic symptoms. The
treatment group had significantly lower overall PAWS scores, with
reductions in somatic symptoms and insomnia and, especially, in
craving (3.5 for treatment group vs. 7.0 for placebo group) as well as
a three-fold higher abstinence rate (47.8%) relative to the placebo
control group (15.2%). No hepatic toxicity was reported.
A second human study [58] examined the therapeutic effect of
l-THP combined with methadone for heroin detoxification. Sixty
patients were randomly divided into two groups: one received
methadone plus l-THP; the other received methadone only. The
primary outcome measures were total amount of methadone used
during detoxification and days of detoxification. The combined
treatment group achieved a 96% rate of successful detoxification,
compared to 73% for the methadone alone group. The combined
group also used significantly less total methadone (275 mg vs. 415
mg) and needed less days for the detoxification treatment (8 days vs.
12 days).
Although the effects of l-THP in cocaine-addicted populations
has not yet been studied, due primarily to the lack of approval for
testing in the U.S., these human studies, when considered along with
our preclinical studies, provide compelling evidence to support the use
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of l-THP as an effective new medication for the treatment of drug
addiction with a non-opioid mechanism and anti-craving efficacy.

Safety Profile
The availability of l-THP on the Chinese market since the early
1960’s and its widespread use in a variety of patient populations, as
well as its regulation by the Chinese SFDA, should position l-THP as a
safe medication rather than as an unregulated and potentially
dangerous botanical product. According to the Chinese pharmacopeia
[6] and drug labeling, l-THP is safe at the recommended therapeutic
dosage range (60-180 mg). At higher doses, adverse effects include
sleepiness, dizziness, and nausea. Overdose can cause respiratory
inhibition and, consistent with other drugs with dopamine receptor
antagonist properties, extrapyramidal symptoms. There appears to be
only a few reported cases of allergic reactions upon the use of l-THP.
Despite its longstanding safety record in China, some l-THP containing
preparations, most notably Jin Bu Huan, an adulterated herbal
product, are currently banned by the FDA for human consumption in
the US due to concerns about toxicity [59, 60]. However, reports of
hepatitis [60, 61] and CNS depression [59] related to the l-THP
containing preparation, Jin Bu Huan, were likely related, in part, to
contamination and improper use issues common to many unregulated
herbal products. Final determination of the safety of l-THP awaits more
methodical testing of the effects of standardized doses of purified lTHP. Accordingly, there has been a recent push towards re-evaluation
of l-THP by the FDA.

Future Perspective
Although the results from preclinical experiments and
preliminary Chinese clinical trials suggest that l-THP has great
potential for the treatment of cocaine addiction, there are a number of
obstacles that must be overcome before l-THP can be considered for
approved use in cocaine-dependent populations in the United States.
Foremost among these are concerns about the safety of l-THP, which
are largely secondary to issues with l-THP containing botanical
preparations and known problems with previously evaluated dopamine
antagonist drugs. In the former case, distancing the safety profile of lFuture Medicinal Chemistry, Vol. 4, No. 2 (February 2012): pg. 177-186. DOI. This article is © Future Science and
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THP from those of unregulated botanical preparations while leveraging
the large body of available evidence that has been accumulated across
years of approved and regulated use of Rotundine in China is critical.
Notably, while the clinical data from China provide important “proof of
concept” of l-THP’s efficacy and indication of its safety, additional
testing in man consistent with FDA standards will be essential. This
will, of course, require the approval of l-THP as a new investigational
drug by FDA. With regards to concerns about dopamine antagonist
drugs that have been previously advanced as potential anti-addiction
medications, further evidence to support the claim that l-THP is
distinct from and superior to these drugs (e.g., alpha-flupenthixol) is
needed. Although there are some indications that the pharmacological
profile of l-THP is unique and positively distinguishes it from other
dopamine antagonist drugs in terms of safety and efficacy, our
understanding of the mechanisms of action of l-THP remains
somewhat limited. In particular, side-by-side comparison with other
dopamine antagonist drugs is needed in order to more convincingly
make the case that l-THP does not share the shortcomings (e.g.,
extrapyramidal effects, sedation) that have prevented their approval
as anti-addiction medications.
In the event that l-THP does not receive FDA approval, there is
still much to be learned from its unique pharmacological mechanisms.
At minimum, the demonstrated efficacy of l-THP in preclinical models
and clinical studies suggests that the development or identification of
compounds with more complex pharmacological effects that include
actions at multiple monoamine receptors (not just D1 and D2
dopamine receptors) or the formulation of “drug cocktail” approaches
may represent promising new strategies for the treatment of addiction.
Interestingly, l-THP represents just one of series of naturally-occurring
tetrahydroprotoberberine compounds with similar pharmacological
profiles. Compounds such as l-SPD, which has a similar binding profile
as l-THP but functions as a partial agonist at D1 dopamine receptors
[32] may serve as provocative new platforms for development as antiaddiction medications and, along with l-THP, could provide starting
points for targeted redesign using medicinal chemistry.
Finally, the extant data supporting the use of l-THP (and related
compounds) for the treatment of cocaine addiction suggest potential
utility for the pharmacological management of addiction to other drugs
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of abuse. Indeed, clinical trials demonstrating efficacy in recovering
heroin addicts [57, 58] along with studies showing efficacy in
preclinical models of opiate abuse [62] suggest that l-THP may be
effective for treating addiction to heroin. Studies examining its
potential use in other addiction populations (alcohol, nicotine) are
currently ongoing and should provide additional understanding about
the therapeutic utility of l-THP in the near future.

Executive Summary
Treatment of Cocaine Addiction






Despite its societal impact, cocaine addiction persists as a
serious medical condition for which no FDA-approved medication
exists.
An ideal medication for treating addiction should attenuate
cocaine’s rewarding effects and at the same time reduce drug
craving, thus preventing relapse.
The multifaceted nature of cocaine addiction and its underlying
neurobiology suggests that multiple-drug (“cocktail”) therapy or
compounds with more complex pharmacological profiles will be
necessary for effective treatment.

Pharmacology of L-Tetrahydropalmatine




The tetrahydroprotoberberine, l-THP, has a pharmacokinetic and
pharmacological profile that may be optimal for treating cocaine
addiction.
The pharmacological profile of l-THP includes antagonism of
dopamine D1, and D2 receptors as well as actions at dopamine
D3, alpha adrenergic and serotonin receptors.

Preclinical Studies of L-THP




l-THP is effective in preclinical models that examine effects on
the reinforcing/rewarding/subjective effects of cocaine as well as
in models of relapse.
In these preclinical models, l-THP is effective at doses that fail
to produce non-specific motor impairment and/or sedation.
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Clinical Use and Studies Of L-THP








L-THP has a pharmacokinetic profile that is favorable for clinical
use.
l-THP has a long-standing record of safe use in China for a
number of indications under the trade-name Rotundine.
Concerns about liver toxicity and sedation associated with the
use of some l-THP containing herbal preparations in the US are
likely due to poor quality and improper use of these unregulated
products.
Preliminary clinical studies investigating the effects of l-THP in
human heroin addict populations have yielded promising results.
Additional clinical examination of the efficacy of l-THP in human
cocaine addict populations is needed.
Testing in human populations in the US awaits further
demonstration to the FDA that l-THP is safe for human
consumption at doses that effectively manage addiction.
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